Detalles de la búsqueda
1.
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
Clin Cancer Res;
29(17): 3384-3394, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432976
2.
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Eur J Cancer;
148: 159-170, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743484
3.
Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial.
Clin Cancer Res;
27(8): 2148-2158, 2021 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33542080
4.
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.
Clin Cancer Res;
26(8): 1896-1904, 2020 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31932495
5.
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Breast Cancer Res;
21(1): 142, 2019 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829264
6.
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
J Clin Oncol;
36(22): 2281-2287, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29791287
7.
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
BMC Cancer;
18(1): 265, 2018 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29514593
8.
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
Breast Cancer Res Treat;
167(1): 59-71, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28875243
9.
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Lancet Oncol;
19(1): 40-50, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29233559
10.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Breast Cancer Res Treat;
156(1): 81-9, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26909792
11.
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Pharmacoeconomics;
33(2): 179-90, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25404424
12.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Breast Cancer Res;
16(2): R38, 2014 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24725534
13.
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
BMC Cancer;
12: 456, 2012 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23039280
14.
Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.
J Clin Pathol;
65(7): 660-2, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22447922
15.
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Virchows Arch;
460(3): 251-9, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22371223
16.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Clin Cancer Res;
17(18): 6012-20, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21807638
Resultados
1 -
16
de 16
1
Próxima >
>>